Ritonavir
Cat.No:IR0460 Solarbio
CAS:155213-67-5
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My CartCAS:155213-67-5
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 155213-67-5 |
Name | Ritonavir |
Molecular Formula | C37H48N6O5S2 |
Molecular Weight | 720.94 |
Solubility | Soluble in DMSO |
Purity | ≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 208-127-9 |
MDL | MFCD00927142 |
SMILES | O=C(N[C@@H](CC1=CC=CC=C1)[C@H](C[C@H](CC2=CC=CC=C2)NC([C@H](C(C)C)NC(N(CC3=CSC(C(C)C)=N3)C)=O)=O)O)OCC4=CN=CS4 |
Target Point | HIV Protease |
Passage | Anti-infection |
Background | Ritonavir is an inhibitor of HIV protease. |
Biological Activity | Ritonavir是用于治疗HIV感染和AIDS的 HIV蛋白酶的抑制剂。[1-5] |
In Vitro | 利托那韦是CYP3A4介导的睾酮6β-羟基化的抑制剂,平均Ki为19 nM,并且还抑制甲苯磺丁脲羟基化,IC50为4.2μM[1]。发现利托那韦是CYP3A介导的生物转化的有效抑制剂(硝苯地平氧化,IC50为0.07mM,17α-乙炔基雌二醇2-羟基化,IC50为2mM;特非那定羟基化,IC50为0.14mM)。利托那韦也是由CYP2D6(IC50 = 2.5 mM)和CYP2C9/10(IC50 = 8.0 mM)介导的反应的抑制剂[2]。利托那韦导致未感染的人PBMC培养物中细胞活力的增加。利托那韦显著降低PBMC对凋亡的易感性,其与较低水平的胱天蛋白酶-1表达相关,在膜联蛋白V染色中降低,并且在未感染的人PBMC培养物中降低胱天蛋白酶-3活性。利托那韦在无毒浓度下抑制PBMC和单核细胞以时间和剂量依赖性方式诱导肿瘤坏死因子(TNF)的产生[3]。利托那韦抑制p-糖蛋白介导的沙奎那韦挤压,IC50为0.2μM,表明利托那韦对p-糖蛋白具有高亲和力[4]。利托那韦有效抑制ABT-378的人肝微粒体代谢,Ki为13 nM。利托那韦联合ABT-378(比例为3:1和29:1)可抑制CYP3A(IC50 = 1.1和4.6μM),尽管效果不如利托那韦(IC50 =0.14μM)[5]。 |
Data Literature Source | [1]. Eagling VA,et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors,ritonavir,saquinavir and indinavir. Br J Clin Pharmacol. 1997 Aug;44(2):190-4. [2]. Kumar GN,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277(1):423-31. [3]. Weichold FF,et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2(5):261-9. [4]. Drewe J,et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57(10):1147-52. [5]. Kumar GN,et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27(8):902-8. |
Unit | Bottle |
Specification | 10mg 50mg 100mg |
Ritonavir是一种 HIV蛋白酶的抑制剂。
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.